{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:49Z","timestamp":1787960209241,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jacc.2019.02.048","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T09:24:19Z","timestamp":1557307459000},"page":"2243-2250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction"],"prefix":"10.1016","volume":"73","author":[{"given":"Keith A.A.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shestakovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj P.","family":"Metsarinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.02.048_bib1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the\u00a0anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.048_bib2","doi-asserted-by":"crossref","first-page":"h246","DOI":"10.1136\/bmj.h246","article-title":"The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: Population based observational study","volume":"350","author":"Jun","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.02.048_bib3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.048_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2019.02.048_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1378\/chest.10-2961","article-title":"The HAS-BLED score and renal failure","volume":"139","author":"Vazquez","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2019.02.048_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A\u00a0new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study","volume":"58","author":"Fang","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.048_bib7","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.048_bib8","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.jacc.2006.12.049","article-title":"The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 Study","volume":"49","author":"Fox","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.048_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-147-5-200709040-00005","article-title":"Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non\u2013ST-segment elevation acute coronary syndromes","volume":"147","author":"Fox","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.02.048_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.048_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.048_bib12","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.048_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.048_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.048_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an Update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.048_bib16","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.048_bib17","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.048_bib18","first-page":"1027","article-title":"Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2019.02.048_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.048_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without ASA in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.048_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without ASA in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.048_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1755-5922.12083","article-title":"The \u201cdual-pathway\u201d strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 Trial","volume":"32","author":"Cohen","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jacc.2019.02.048_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4330\/wjc.v7.i7.397","article-title":"Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease","volume":"7","author":"Patel","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jacc.2019.02.048_bib24","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2019.02.048_bib25","first-page":"1791","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","author":"Bonaca","year":"2015372","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.048_bib26","first-page":"6248","article-title":"Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review","author":"Harmon","year":"201322","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jacc.2019.02.048_bib27","first-page":"687","article-title":"The efficacy and safety of short and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","author":"Best","year":"2008155","journal-title":"Am Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719344079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719344079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:21:00Z","timestamp":1760016060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719344079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0735109719344079"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.02.048","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.02.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}